Investigational ADC Shows Promise in Advanced Endometrial Cancer

[ad_1]

(MedPage Today) — Puxitatug samrotecan (P-Sam), an investigational antibody-drug conjugate (ADC) targeting B7-H4-expressing tumors, showed promising efficacy in patients with advanced or metastatic endometrial cancer, according to results from…

[ad_2]

Source link : https://www.medpagetoday.com/meetingcoverage/sgo/114718

Author :

Publish date : 2025-03-18 20:06:00

Copyright for syndicated content belongs to the linked Source.